Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Alnylam Pharmaceuticals Inc shares valued at $1,727,284 were sold by Poulton Jeffrey V. on Oct 02 ’25. At $452.05 per share, Poulton Jeffrey V. sold 3,821 shares. The insider’s holdings dropped to 54,052 shares worth approximately $24.36 million following the completion of this transaction.
Also, Greenstreet Yvonne sold 8,924 shares, netting a total of over 4,034,085 in proceeds. Following the sale of shares at $452.05 each, the insider now holds 65,409 shares.
Before that, Tanguler Tolga had sold 1,405 shares from its account. In a trade valued at $635,126, the EVP, Chief Commercial Officer traded Alnylam Pharmaceuticals Inc shares for $452.05 each. Upon closing the transaction, the insider’s holdings decreased to 1,405 shares, worth approximately $12.37 million.
As published in a research note from Wolfe Research on August 04, 2025, Alnylam Pharmaceuticals Inc [ALNY] has been rated up from an Underperform to a Peer perform. Analysts at Oppenheimer upgraded the stock from ‘”a Perform”‘ to ‘”an Outperform”‘ outlook in a report released in early August. Earlier on July 21, 2025, Truist initiated its rating. Their recommendation was “a Buy” for ALNY stock.
Analyzing ALNY Stock Performance
On last trading session, Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] plunged -1.94% to $450.68. The stock’s lowest price that day was $449.72, but it reached a high of $464.46 in the same session. During the last five days, there has been a drop of approximately -2.16%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 68.17%. Shares of the company reached a 52-week high of $484.21 on 09/09/25 and a 52-week low of $205.87 on 04/09/25.
Support And Resistance Levels for Alnylam Pharmaceuticals Inc (ALNY)
According to the 24-hour chart, there is a support level at 445.45, which, if violated, would cause prices to drop to 440.21. In the upper region, resistance lies at 460.19. The next price resistance is at 469.69. RSI (Relative Strength Index) is 49.60 on the 14-day chart, showing neutral technical sentiment.
Is Alnylam Pharmaceuticals Inc subject to short interest?
Stocks of Alnylam Pharmaceuticals Inc saw a sharp rise in short interest on 2025-09-15 jumping by 0.29 million shares to 3.72 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 3.43 million shares. A jump of 7.85% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.28 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.28.
Which companies own the most shares of Alnylam Pharmaceuticals Inc (ALNY)?
In terms of Alnylam Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 470 in the next 12 months, up nearly 2.27% from the previous closing price of $459.58. Analysts anticipate Alnylam Pharmaceuticals Inc stock to reach 495 by 2025, with the lowest price target being 370. In spite of this, 20 analysts ranked Alnylam Pharmaceuticals Inc stock as Buy at the end of 2025. On March 31, 2025, Redburn Atlantic assigned a price target of “a Buy” to the stock and initiated coverage with a $353.
